{"nctId":"NCT00364156","briefTitle":"Comparison of Standard Versus Extended Nicotine Patch Therapy for Smoking Cessation","startDateStruct":{"date":"2004-06"},"conditions":["TOBACCO USE CESSATION"],"count":568,"armGroups":[{"label":"Extended Patch Treatment","type":"EXPERIMENTAL","interventionNames":["Drug: 24-weeks of nicotine patch"]},{"label":"Standard Patch Treatment","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Standard Patch Treatment"]}],"interventions":[{"name":"Standard Patch Treatment","otherNames":[]},{"name":"24-weeks of nicotine patch","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Males and females of descent between the ages of 18-65 who smokes at least 10 cigarettes/day and are seeking smoking cessation treatment.\n2. Based on the medical history, physical and laboratory examination, premenopausal female subjects must consent to practice an effective form of contraception during study.\n3. Following orientation by the research staff, subjects must sign written informed consent for all study procedures.\n\nExclusion Criteria:\n\n1. Women who are pregnant, planning a pregnancy, or lactating.\n2. Current medical problems for which TN is contraindicated including allergy to nicotine, uncontrolled hypertension, unstable angina, serious arrhythmia, heart attack or stroke within the past 6 months, liver and/or kidney failure in the last 6-months and current diabetes.\n3. Current treatment of cancer or diagnosed with cancer in the past 6 months\n4. Current DSM IV substance use disorders (dependence involving alcohol, cocaine, marijuana or stimulants, benzodiazepines).\n5. Current use of TN or other forms of NRT.\n6. Concomitant medications (e.g., monoamine oxidase inhibitors or benzodiazepines within past 14 days, antipsychotics, endogenous steroids, and antidepressants (including wellbutrin or bupropion).","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Biochemically Verified 7-day Point Prevalence Abstinence","description":"To evaluate the efficacy of standard (8-week) vs. extended (24-week) transdermal nicotine therapy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":282},"commonTop":["Hypertension","Agressive Thoughts","Seizure during Blood Draw"]}}}